BioGaia AB (publ) (BIOG-B.ST)
SEK 101.1
(2.17%)
SEK 101.1
(2.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 950.19 Million SEK | 18.49% |
| 2022 | 801.93 Million SEK | 37.56% |
| 2021 | 582.95 Million SEK | 6.59% |
| 2020 | 546.91 Million SEK | -3.03% |
| 2019 | 563.99 Million SEK | 1.45% |
| 2018 | 555.91 Million SEK | 19.98% |
| 2017 | 463.34 Million SEK | 19.48% |
| 2016 | 387.8 Million SEK | 15.22% |
| 2015 | 336.58 Million SEK | -3.96% |
| 2014 | 350.46 Million SEK | 63.64% |
| 2013 | 214.16 Million SEK | -61.56% |
| 2012 | 557.07 Million SEK | 157.59% |
| 2011 | 216.26 Million SEK | 36.12% |
| 2010 | 158.88 Million SEK | 17.42% |
| 2009 | 135.31 Million SEK | 39.56% |
| 2008 | 96.95 Million SEK | 35.68% |
| 2007 | 71.45 Million SEK | 20.8% |
| 2006 | 59.15 Million SEK | 52.84% |
| 2005 | 38.7 Million SEK | 56.06% |
| 2004 | 24.8 Million SEK | 0.63% |
| 2003 | 24.64 Million SEK | 70.46% |
| 2002 | 14.45 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 265.83 Million SEK | 17.94% |
| 2024 Q2 | 284.04 Million SEK | 6.85% |
| 2024 Q3 | 222.33 Million SEK | -21.72% |
| 2023 FY | 950.19 Million SEK | 18.49% |
| 2023 Q2 | 226.43 Million SEK | -13.74% |
| 2023 Q1 | 262.51 Million SEK | 26.21% |
| 2023 Q4 | 225.39 Million SEK | -4.43% |
| 2023 Q3 | 235.84 Million SEK | 4.16% |
| 2022 Q2 | 205.94 Million SEK | 1.85% |
| 2022 Q3 | 185.78 Million SEK | -9.79% |
| 2022 FY | 801.93 Million SEK | 37.56% |
| 2022 Q1 | 202.2 Million SEK | 27.15% |
| 2022 Q4 | 207.99 Million SEK | 11.96% |
| 2021 Q4 | 159.03 Million SEK | 24.37% |
| 2021 FY | 582.95 Million SEK | 6.59% |
| 2021 Q1 | 145.2 Million SEK | 3.74% |
| 2021 Q2 | 150.84 Million SEK | 3.89% |
| 2021 Q3 | 127.86 Million SEK | -15.24% |
| 2020 Q4 | 139.96 Million SEK | 56.38% |
| 2020 Q1 | 133 Million SEK | -13.74% |
| 2020 Q2 | 184.44 Million SEK | 38.67% |
| 2020 Q3 | 89.5 Million SEK | -51.47% |
| 2020 FY | 546.91 Million SEK | -3.03% |
| 2019 Q3 | 121.96 Million SEK | -25.37% |
| 2019 FY | 563.99 Million SEK | 1.45% |
| 2019 Q1 | 124.41 Million SEK | -21.05% |
| 2019 Q4 | 154.18 Million SEK | 26.41% |
| 2019 Q2 | 163.43 Million SEK | 31.36% |
| 2018 Q2 | 151.99 Million SEK | 31.29% |
| 2018 Q4 | 157.58 Million SEK | 20.68% |
| 2018 FY | 555.91 Million SEK | 19.98% |
| 2018 Q1 | 115.76 Million SEK | -11.71% |
| 2018 Q3 | 130.57 Million SEK | -14.09% |
| 2017 Q1 | 105.74 Million SEK | 1.63% |
| 2017 Q4 | 131.11 Million SEK | 20.49% |
| 2017 Q3 | 108.82 Million SEK | -7.51% |
| 2017 FY | 463.34 Million SEK | 19.48% |
| 2017 Q2 | 117.66 Million SEK | 11.27% |
| 2016 Q4 | 104.05 Million SEK | 13.99% |
| 2016 Q2 | 97.7 Million SEK | 3.09% |
| 2016 Q1 | 94.77 Million SEK | 29.19% |
| 2016 FY | 387.8 Million SEK | 15.22% |
| 2016 Q3 | 91.28 Million SEK | -6.57% |
| 2015 Q1 | 97.83 Million SEK | 28.39% |
| 2015 FY | 336.58 Million SEK | -3.96% |
| 2015 Q4 | 73.36 Million SEK | 2.13% |
| 2015 Q3 | 71.83 Million SEK | -23.22% |
| 2015 Q2 | 93.55 Million SEK | -4.38% |
| 2014 Q2 | 65.28 Million SEK | -58.39% |
| 2014 Q3 | 52.07 Million SEK | -20.24% |
| 2014 Q4 | 76.2 Million SEK | 46.34% |
| 2014 Q1 | 156.9 Million SEK | 165.44% |
| 2014 FY | 350.46 Million SEK | 63.64% |
| 2013 FY | 214.16 Million SEK | -61.56% |
| 2013 Q2 | 59.88 Million SEK | 15.25% |
| 2013 Q4 | 59.11 Million SEK | 36.8% |
| 2013 Q3 | 43.21 Million SEK | -27.84% |
| 2013 Q1 | 51.96 Million SEK | 8.04% |
| 2012 Q4 | 48.09 Million SEK | 11.04% |
| 2012 Q3 | 43.31 Million SEK | -19.99% |
| 2012 Q2 | 54.13 Million SEK | -2.5% |
| 2012 Q1 | 55.52 Million SEK | -2.99% |
| 2012 FY | 557.07 Million SEK | 157.59% |
| 2011 Q4 | 57.23 Million SEK | 19.69% |
| 2011 Q1 | 48.51 Million SEK | 11.93% |
| 2011 Q2 | 62.69 Million SEK | 29.21% |
| 2011 Q3 | 47.82 Million SEK | -23.72% |
| 2011 FY | 216.26 Million SEK | 36.12% |
| 2010 Q1 | 39.27 Million SEK | 9.79% |
| 2010 Q3 | 32.14 Million SEK | -27.14% |
| 2010 FY | 158.88 Million SEK | 17.42% |
| 2010 Q2 | 44.12 Million SEK | 12.35% |
| 2010 Q4 | 43.34 Million SEK | 34.85% |
| 2009 Q2 | 37.52 Million SEK | 5.88% |
| 2009 Q1 | 35.44 Million SEK | 0.0% |
| 2009 FY | 135.31 Million SEK | 39.56% |
| 2009 Q4 | 35.76 Million SEK | 34.58% |
| 2009 Q3 | 26.57 Million SEK | -29.18% |
| 2008 Q2 | 23.36 Million SEK | 0.0% |
| 2008 FY | 96.95 Million SEK | 35.68% |
| 2007 FY | 71.45 Million SEK | 20.8% |
| 2006 FY | 59.15 Million SEK | 52.84% |
| 2005 FY | 38.7 Million SEK | 56.06% |
| 2004 FY | 24.8 Million SEK | 0.63% |
| 2003 FY | 24.64 Million SEK | 70.46% |
| 2002 FY | 14.45 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -14314.29% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 199719.748% |
| Enzymatica AB (publ) | 31.86 Million SEK | -2882.111% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 24457.601% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 10557766.667% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 45368.699% |
| Nanexa AB (publ) | 59.15 Million SEK | -1506.217% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | -5826.464% |
| ODI Pharma AB | -1.34 Million SEK | 70923.287% |
| Orexo AB (publ) | 549.9 Million SEK | -72.793% |
| Probi AB (publ) | 220.21 Million SEK | -331.487% |
| Swedencare AB (publ) | 164.8 Million SEK | -476.572% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 93.239% |
| Toleranzia AB | -919 Thousand SEK | 103493.906% |
| Vivesto AB | -10.65 Million SEK | 9016.948% |